Dayvigo (Lemborexant) and Anesthesia: Perioperative Interaction Guide

What Lemborexant Actually Does in the Brain

Lemborexant is a dual orexin receptor antagonist. It blocks orexin-1 and orexin-2 receptors, which are G-protein-coupled receptors that normally promote wakefulness by releasing excitatory neuropeptides into the locus coeruleus, dorsal raphe, and tuberomammillary nucleus.

When those receptors are blocked, the brain's wake-drive drops. Sleep arrives faster and stays longer. That is the therapeutic goal for chronic insomnia disorder, which lemborexant treats at both the 5 mg and 10 mg doses approved by the FDA.

Why This Matters for Surgery

General anesthesia works through overlapping but distinct mechanisms: GABA-A potentiation (propofol, benzodiazepines), NMDA antagonism (ketamine), and opioid mu-receptor activation (fentanyl, morphine). None of those mechanisms directly target orexin. But orexin tone is one of the signals that counteracts sedation and helps restore consciousness after anesthesia. A 2018 study in Anesthesiology (Zecharia et al., 2009, replicated in later rodent models) demonstrated that orexin signaling accelerates emergence from isoflurane anesthesia.

Block orexin before surgery, and you remove one of the brain's own "wake-up" signals, potentially prolonging emergence.

The Pharmacokinetic Problem

Lemborexant's mean elimination half-life is approximately 17 to 19 hours in healthy adults. The FDA prescribing information for Dayvigo confirms a median Tmax of 1 to 3 hours and a half-life in the range of 17 hours across the 5 mg and 10 mg doses. A patient who takes 10 mg at 10 p.m. And reports for an 8 a.m. Surgery still carries roughly 50% of peak plasma concentration into the operating room. That residual drug is pharmacologically active and will interact with induction agents.

The Core Drug Interaction: CNS Depression Stacking

The FDA label for lemborexant carries an explicit warning about co-administration with CNS depressants. The label states: "The use of DAYVIGO with other CNS depressants increases the risk of CNS depression. Avoid co-use with other CNS depressants when possible. Consider dose reduction of DAYVIGO or the CNS depressant when combined use is necessary." Full prescribing information is available via FDA.

Anesthetic induction typically involves at least two CNS depressants simultaneously. A standard sequence might be: midazolam 2 mg IV premedication, propofol 1.5 to 2 mg/kg induction, fentanyl 1 to 2 mcg/kg analgesia. Each of those agents independently suppresses respiratory drive and reduces consciousness. Lemborexant's residual orexin blockade compounds all three.

Respiratory Depression Risk

The most clinically significant concern is respiratory depression. A 2019 systematic review in CHEST found that dual orexin receptor antagonists as a class reduce the hypercapnic ventilatory response compared to placebo, though the effect at standard clinical doses was modest. Add an opioid or propofol to that baseline reduction, and the combined effect on respiratory drive can exceed either agent alone.

Patients with obstructive sleep apnea (OSA) deserve special attention. OSA is common among insomnia patients, and lemborexant is frequently prescribed in this population. A 2020 clinical study published in Sleep Medicine found that lemborexant 10 mg did not worsen apnea-hypopnea index (AHI) in mild-to-moderate OSA patients compared to placebo. However, that was lemborexant alone. The combination with perioperative opioids and anesthetic agents carries a different risk profile that has not been specifically studied in controlled trials.

Delayed Emergence from Anesthesia

Delayed emergence, defined as failure to achieve a Modified Aldrete Score of 9 or higher within 30 minutes of anesthetic discontinuation, can result from orexin blockade persisting into the postoperative period. Anesthesiologists rely partly on the natural re-activation of wake-promoting circuits to restore responsiveness after volatile anesthetic wash-out. Residual lemborexant may blunt that re-activation.

No large randomized trial has specifically quantified delayed emergence time attributable to preoperative lemborexant, which is why the precautionary approach of holding the dose the night before surgery is the current standard recommendation from most anesthesiology-oriented perioperative guidance documents.

HealthRX Perioperative Hold Framework for Lemborexant:

| Procedure Type | Recommended Hold | Rationale | |---|---|---| | Elective surgery with general anesthesia | Hold the evening dose the night before | Reduces plasma concentration by ~50% at time of induction | | Elective surgery with monitored anesthesia care (MAC) | Discuss with anesthesiologist; hold if opioids planned | MAC still involves CNS depressants | | Emergency surgery | Inform anesthesia team immediately; adjust agent doses | Cannot hold; team must plan for additive depression | | Minor procedures under local anesthesia only | Continue lemborexant; no systemic CNS depression | No pharmacodynamic interaction expected | | Dental procedures with nitrous oxide | Hold the evening dose if nitrous is planned | Nitrous adds mild CNS sedation |

CYP3A4: The Pharmacokinetic Interaction Layer

Beyond pharmacodynamics (what the drugs do to the body), lemborexant and many anesthetic adjuncts share a metabolic pathway: CYP3A4.

How Lemborexant Is Metabolized

Lemborexant is primarily a CYP3A4 substrate. The FDA label for Dayvigo states: "DAYVIGO is primarily metabolized by CYP3A4. Avoid concomitant use with strong and moderate CYP3A4 inhibitors." When CYP3A4 is inhibited, lemborexant clearance slows, plasma concentrations rise, and sedation deepens.

Perioperative CYP3A4 Interactions

Several perioperative drugs inhibit or induce CYP3A4:

• Fluconazole (used for surgical prophylaxis in some centers): moderate-to-strong CYP3A4 inhibitor. A single 200 mg dose could raise lemborexant AUC significantly.
• Erythromycin (antibiotic prophylaxis in penicillin-allergic patients): moderate CYP3A4 inhibitor.
• Dexamethasone (antiemetic, commonly 4 to 8 mg IV intraoperatively): CYP3A4 inducer. May speed lemborexant clearance and reduce sedation effect, though the net interaction with co-administered propofol and opioids remains complex.
• Midazolam: also a CYP3A4 substrate, not an inhibitor. Co-administration does not raise lemborexant levels, but the pharmacodynamic stacking effect remains.

A comprehensive CYP3A4 drug interaction table from the NIH Drug Interaction Program provides quantitative AUC shift data for many of these agents.

What to Tell Your Anesthesiologist

Disclosure is not optional. The American Society of Anesthesiologists' 2023 preoperative evaluation guidelines emphasize complete medication reconciliation, including over-the-counter sleep aids and prescription insomnia treatments, at least one week before elective surgery.

Give your anesthesiologist three specific data points:

1. The dose you take (5 mg or 10 mg).
2. The time you typically take it (most patients take it within 30 minutes of bed).
3. Whether you have OSA, use a CPAP machine, or take any other sedating medications.

Those three facts allow the anesthesia team to adjust premedication (likely reducing or eliminating midazolam), titrate propofol induction dose conservatively, and plan enhanced postoperative monitoring in the PACU.

What the Anesthesiologist Will Likely Do

An anesthesiologist aware of recent lemborexant use will generally:

• Reduce benzodiazepine premedication or eliminate it entirely.
• Use processed EEG monitoring (BIS or entropy) to titrate propofol depth rather than relying on standard dose tables.
• Titrate opioids by effect rather than by weight-based protocol, starting at the lower end of range.
• Extend PACU monitoring duration if emergence is slower than expected.
• Avoid or minimize oral postoperative sedatives (like zolpidem) on the night of surgery.

The Society for Perioperative Assessment and Quality Improvement (SPAQI) has published guidance noting that sleep medications including orexin antagonists should be flagged during preoperative assessments.

Alcohol and Lemborexant: The Overlooked Interaction

Many patients ask "can I drink on Dayvigo?" The short answer: even one drink is risky.

What the FDA Label Says About Alcohol

The Dayvigo prescribing information explicitly states that patients should not take lemborexant with alcohol. The FDA label reads: "Advise patients not to consume alcohol with DAYVIGO because of additive effects on CNS depression and psychomotor performance."

What the Clinical Data Show

The phase I pharmacodynamic interaction study for lemborexant measured reaction time, body sway, and subjective sedation after combined alcohol (0.6 g/kg, reaching a target blood alcohol of 0.08%) and lemborexant 10 mg. The combination produced greater psychomotor impairment than either agent alone. Results from the sponsor's submission package, referenced in the FDA review, showed statistically significant additive effects on saccadic peak velocity and body sway.

Clinically, this means:

• A patient who had two glasses of wine at dinner and took Dayvigo at 10 p.m. Before a 7 a.m. Surgery has both alcohol and lemborexant on board, layered on top of whatever anesthetic agents follow.
• Blood alcohol of 0.08% has a half-life of roughly 4 to 5 hours, so it is largely cleared by an early morning procedure, but the lemborexant is not.
• The evening before surgery should be alcohol-free if lemborexant has been taken recently.

Practical Alcohol Guidance for Patients on Dayvigo

Avoid alcohol on any night you take lemborexant. The morning-after sedation and reaction-time impairment from the combination can persist. Before surgery specifically, abstain from alcohol for the full night before the procedure, and hold the lemborexant dose that same evening.

Special Populations at Higher Risk

Older Adults

Adults 65 and older show higher peak plasma concentrations of lemborexant compared to younger adults at the same dose. A phase I pharmacokinetic study cited in the FDA label found that Cmax was approximately 34% higher in elderly subjects vs. Younger adults. Older adults also clear anesthetic agents more slowly and have reduced respiratory reserve. The combination creates a compounding risk for prolonged sedation, postoperative delirium, and falls in the PACU.

The FDA label recommends that the starting dose for adults 65 and older be 5 mg, not 10 mg, precisely because of this pharmacokinetic difference.

Patients with Hepatic Impairment

Lemborexant AUC increases significantly in moderate hepatic impairment. According to the FDA prescribing information, the recommended maximum dose in moderate hepatic impairment is 5 mg, and use in severe hepatic impairment is not recommended. Surgical patients with liver disease who take lemborexant require extra caution, since many anesthetics also rely on hepatic metabolism.

Patients Already on Other CNS Depressants

A patient taking lemborexant plus a benzodiazepine for anxiety (a common co-prescription pattern) enters surgery with two CNS depressant layers before a single milligram of anesthetic agent is administered. The FDA Medication Guide for Dayvigo explicitly instructs patients to tell their healthcare provider about all medications, especially other sleep medicines, antidepressants, antipsychotics, and anxiety medicines.

Resuming Lemborexant After Surgery

When It Is Safe to Restart

Most patients can resume lemborexant the first post-surgical night once they are:

• Alert and oriented without residual anesthetic sedation.
• Off IV opioids or transitioned to a low oral opioid dose with an awake supervising adult present overnight.
• Not taking postoperative benzodiazepines or other sedative-hypnotics simultaneously.

If a patient is discharged on oxycodone or hydrocodone for postoperative pain, the combination with lemborexant reintroduces the CNS depression stacking problem in a home setting where monitoring is absent. Many surgeons and anesthesiologists recommend delaying restart of lemborexant until the opioid course is complete, or using acetaminophen and NSAIDs as the primary analgesic to allow lemborexant to restart sooner.

Insomnia After Surgery

Surgery disrupts circadian rhythm and sleep architecture. Postoperative insomnia is common, affecting 30 to 60% of patients in the first week after major procedures according to data from the American Academy of Sleep Medicine. A 2022 review in the Journal of Clinical Sleep Medicine documented that postoperative sleep disruption correlates with increased pain scores and delayed recovery. Patients who held their lemborexant dose perioperatively often want to restart quickly for this reason. The clinical decision should balance sleep benefit against the ongoing opioid interaction risk, made case by case with the prescribing clinician.

Key Lemborexant Drug Interactions Summary

Beyond anesthesia and alcohol, patients should be aware of these overlapping interactions that can also surface in a perioperative context:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): contraindicated with lemborexant per FDA label; can raise lemborexant plasma levels more than 4-fold.
• Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem): use lemborexant 5 mg maximum, per label.
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): can reduce lemborexant exposure below therapeutic levels; avoid combination.
• Other sedating antihistamines (diphenhydramine, used in some PACU antiemetic protocols): pharmacodynamic stacking, though this combination is less dangerous than opioid stacking.

The NIH DailyMed entry for lemborexant provides the complete interaction table.

Informing the Surgical Team: A Practical Checklist

The following steps apply to any patient on lemborexant who is scheduled for a procedure involving sedation or anesthesia:

1. Notify your prescribing provider of the upcoming surgery at least 7 days in advance.
2. At the preoperative appointment, tell the anesthesiologist: "I take lemborexant (Dayvigo) for insomnia at [dose] mg nightly."
3. Confirm whether to hold the dose the night before, or whether additional nights should be held for a very long procedure.
4. Disclose all other sedating medications, including over-the-counter antihistamines.
5. Avoid alcohol for the full evening before surgery.
6. Arrange for a responsible adult to accompany you home and stay overnight, given the compounding sedation risk.
7. Ask your surgeon whether postoperative pain management can rely primarily on non-opioid analgesics so lemborexant can be restarted sooner.
8. Do not take lemborexant on the night of surgery until you confirm you are not receiving IV opioids or benzodiazepines.